High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients

Keyur Patel, Joseph E. Lucas, J. Will Thompson, Laura G. Dubois, Hans L. Tillmann, Alexander J. Thompson, Diane Uzarski, Robert M. Califf, Martin A. Moseley, Geoffrey S. Ginsburg, John G. McHutchison, Jeanette J. McCarthy, for the MURDOCK Horizon 1 Study Team – 4 March 2011 – Chronic hepatitis C (CHC) infection is a leading cause of endstage liver disease. Current standard‐of‐care (SOC) interferon‐based therapy results in sustained virological response (SVR) in only one‐half of patients, and is associated with significant side effects.

Hepatocyte‐specific hypoxia‐inducible factor‐1α is a determinant of lipid accumulation and liver injury in alcohol‐induced steatosis in mice

Bharath Nath, Ivan Levin, Timea Csak, Jan Petrasek, Christian Mueller, Karen Kodys, Donna Catalano, Pranoti Mandrekar, Gyongyi Szabo – 3 March 2011 – Chronic alcohol causes hepatic steatosis and liver hypoxia. Hypoxia‐regulated hypoxia‐inducible factor 1‐α, (HIF‐1α) may regulate liporegulatory genes, but the relationship of HIF‐1 to steatosis remains unknown. We investigated HIF‐1α in alcohol‐induced hepatic lipid accumulation.

Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus

Jean‐Michel Pawlotsky – 3 March 2011 – Current treatment of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon‐α and ribavirin. The recent development of direct‐acting antiviral (DAA) molecules that are active on HCV, together with in vitro and in vivo studies showing that these drugs may lead to the selection of resistant viruses if administered alone, has raised concerns that resistance may undermine therapy based on DAAs.

Hepatic differentiation of amniotic epithelial cells

Fabio Marongiu, Roberto Gramignoli, Kenneth Dorko, Toshio Miki, Aarati R. Ranade, Maria Paola Serra, Silvia Doratiotto, Marcella Sini, Shringi Sharma, Keitaro Mitamura, Tiffany L. Sellaro, Veysel Tahan, Kristen J. Skvorak, Ewa C. S. Ellis, Stephen F. Badylak, Julio C. Davila, Ronald Hines, Ezio Laconi, Stephen C. Strom – 3 March 2011 – Hepatocyte transplantation to treat liver disease is largely limited by the availability of useful cells.

Subscribe to